Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
Golden, Colorado, Oct. 04, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer, today announces the filing of a Form S-4 with the Securities and Exchange Commission requisite to complete the previously announced merger between the Company
Exciting news for Theralink Technologies
Theralink Technologies, Inc. has recently announced the filing of a Form S-4 with the Securities and Exchange Commission, a significant step towards completing the merger with IMAC Holdings. This merger is highly anticipated and is expected to take place during the fourth quarter of 2023. Theralink is known for its innovative approach to precision oncology, particularly in the field of breast cancer.
Implications for Theralink and IMAC Holdings
The merger between Theralink and IMAC Holdings has the potential to create a powerhouse in the precision oncology industry. By joining forces, the two companies can combine their expertise and resources to further develop and enhance their offerings in the treatment of breast cancer. This merger is expected to bring about new opportunities for growth and innovation, ultimately benefiting patients and healthcare providers alike.
What to expect in the coming months
With the filing of the Form S-4, Theralink Technologies is signaling its commitment to moving forward with the merger with IMAC Holdings. As the two companies work towards completing the necessary steps for the merger, stakeholders can look forward to updates on the progress and potential timelines for the completion of the merger.
How will this affect me?
As a patient or healthcare provider, the merger between Theralink and IMAC Holdings could lead to improved options and treatment outcomes for individuals diagnosed with breast cancer. The combined expertise and resources of the two companies may result in new advancements in precision oncology that could benefit those in need of innovative treatments.
How will this affect the world?
The merger between Theralink Technologies and IMAC Holdings has the potential to make a significant impact on the world of precision oncology. By joining forces, the companies can work towards developing cutting-edge solutions for breast cancer treatment that could have far-reaching effects on healthcare globally. This merger represents a step towards progress and innovation in the fight against cancer.
In conclusion
The filing of the Form S-4 by Theralink Technologies and the anticipated merger with IMAC Holdings mark an exciting chapter in the field of precision oncology. This partnership has the potential to drive advancements in the treatment of breast cancer and bring about new opportunities for growth and innovation. Stakeholders can look forward to witnessing the impact of this merger in the coming months as Theralink and IMAC Holdings work towards a successful integration of their resources and expertise.
